Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

L'Hospitalet de Llobregat-Barcelona, Spain Clinical Trials

A listing of L'Hospitalet de Llobregat-Barcelona, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

OBJECTIVES: Primary - Determine the safe dose level of sunitinib malate that can be combined with exemestane (pilot phase I). - Evaluate the clinical response of neoadjuvant therapy comprising exemestane and sunitinib malate in postmenopausal women with hormone receptor-positive and HER-2 negative primary breast cancer (phase II). Secondary - Evaluate ...

Phase

1.34 miles

Learn More »

Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen

To determine the recommended phase II dose (RPTD) of GDC-0032 in combination with tamoxifen in hormone receptor positive, HER2 negative metastatic breast cancer patients who have progressed after prior endocrine treatment .Description of toxicity profile, severity and frequency of adverse events (observed with the combination of GDC-0032 and tamoxifen To ...

Phase

2.62 miles

Learn More »

Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab Carboplatin PLD Pembrolizumab or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC Primary Peritoneal or Fallopian Tube Cancer

The dose escalation part of the study will assess safety and tolerability and determine the maximum tolerated dose (MTD) for each regimen. The dose expansion of the MTD will assess safety, tolerability and preliminary anti-tumor activity.

Phase

3.23 miles

Learn More »

Pazopanib Hydrochloride Paclitaxel and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer Fallopian Tube Cancer or Peritoneal Cancer

OBJECTIVES Primary To determine the maximum-tolerated dose of pazopanib hydrochloride in combination with paclitaxel and carboplatin in patients with platinum-refractory or -resistant ovarian epithelial, fallopian tube, or peritoneal carcinoma. (Phase I) To determine the progression-free survival (PFS) at 1 year according to the RECIST 1.1 in these patients. (Phase II) ...

Phase

8.69 miles

Learn More »